Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/126017
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sandoval, Juan | - |
dc.contributor.author | Méndez González, Jesús | - |
dc.contributor.author | Nadal, Ernest | - |
dc.contributor.author | Chen, Guoan | - |
dc.contributor.author | Carmona, F. Javier | - |
dc.contributor.author | Sayols, Sergi | - |
dc.contributor.author | Moran, Sebastian | - |
dc.contributor.author | Heyn, Holger | - |
dc.contributor.author | Vizoso, Miguel | - |
dc.contributor.author | Gómez, Antonio | - |
dc.contributor.author | Sánchez Céspedes, Montserrat | - |
dc.contributor.author | Assenov, Yassen | - |
dc.contributor.author | Müller, Fabian | - |
dc.contributor.author | Bock, Christoph | - |
dc.contributor.author | Taron, Miquel | - |
dc.contributor.author | Mora, Josefina | - |
dc.contributor.author | Muscarella, Lucia A. | - |
dc.contributor.author | Liloglou, Triantafillos | - |
dc.contributor.author | Davies, Michael P. A. | - |
dc.contributor.author | Pollán, Marina | - |
dc.contributor.author | Pajares, María José | - |
dc.contributor.author | Torre, Wenceslao | - |
dc.contributor.author | Montuenga, Luis M. | - |
dc.contributor.author | Brambilla, Elisabeth | - |
dc.contributor.author | Field, John K. | - |
dc.contributor.author | Roz, Luca | - |
dc.contributor.author | Lo Iacono, Marco | - |
dc.contributor.author | Scagliotti, Giorgio V. | - |
dc.contributor.author | Rosell Costa, R. | - |
dc.contributor.author | Beer, David G. | - |
dc.contributor.author | Esteller, Manel | - |
dc.date.accessioned | 2018-11-12T12:24:15Z | - |
dc.date.available | 2018-11-12T12:24:15Z | - |
dc.date.issued | 2013-11-10 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | http://hdl.handle.net/2445/126017 | - |
dc.description.abstract | Purpose Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard. Patients and Methods A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA methylation markers were validated by a single-methylation pyrosequencing assay in an independent cohort of 143 patients with stage I NSCLC. Results Unsupervised clustering of the 10,000 most variable DNA methylation sites in the discovery cohort identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P = .004). The study in the validation cohort of the significant methylated sites from the discovery cohort found that hypermethylation of five genes was significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished patients with high-and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P = .001). Conclusion The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging. (C) 2013 by American Society of Clinical Oncology. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1200/JCO.2012.48.5516 | - |
dc.relation.ispartof | Journal of Clinical Oncology, 2013, vol. 31, num. 32, p. 4140-4147 | - |
dc.relation.uri | https://doi.org/10.1200/JCO.2012.48.5516 | - |
dc.rights | (c) American Society of Clinical Oncology, 2013 | - |
dc.source | Articles publicats en revistes (Ciències Fisiològiques) | - |
dc.subject.classification | Càncer de pulmó | - |
dc.subject.classification | Metilació | - |
dc.subject.classification | ADN | - |
dc.subject.other | Lung cancer | - |
dc.subject.other | Methylation | - |
dc.subject.other | DNA | - |
dc.title | A prognostic DNA methylation signature for stage I non-small-cell lung cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 662772 | - |
dc.date.updated | 2018-11-12T12:24:15Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/258677/EU//CURELUNG | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
662772.pdf | 2.62 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.